ACR/ARHP Poster Session B 1338. <strong>Rheumatology</strong> Health Pr<strong>of</strong>essionals’ Care: Current and Future Tasks and Education. Emalie J. Hurkmans 3 , Rinie Geenen 1 , John Verhoef 4 and Thea P. M. Vliet Vlieland 2 , 1 Clinical and Health Psychology, Utrecht University & University Medical Center, Utrecht, The Netherlands, 2 Department <strong>of</strong> <strong>Rheumatology</strong> and Orthopaedics, Leiden University Medical Center, Leiden, The Netherlands, 3 Department <strong>of</strong> <strong>Rheumatology</strong>, Leiden University Medical Center, Leiden, The Netherlands, 4 Faculty <strong>of</strong> Health, University <strong>of</strong> Applied Sciences, Leiden, The Netherlands. ARHP Poster Session B: Pediatrics 1339. Accuracy <strong>of</strong> the Early Detection <strong>of</strong> Juvenile Idiopathic Arthritis Questionnaire – A Multicenter Study. Claudio A. Len 7 , Luciana T. P. Paulo 7 , Maria Teresa R. A. Terreri 7 , Silvana B. Sacchetti 3 , Virginia P. L. Ferriani 5 , Clovis A. A. Silva 4 , Cássia M. P. Barbosa 1 , Simone Lotufo 2 and Roberto Marini 6 , 1 Hospital Darcy Vargas, São Paulo, Brazil, 2 Hospital Menino Jesus, São Paulo, Brazil, 3 Santa Casa de São Paulo, São Paulo, Brazil, 4 Universidade de São Paulo, São Paulo, Brazil, 5 Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil, 6 Universidade Estadual de Campinas, São Paulo, Brazil, 7 Universidade Federal de São Paulo, São Paulo, Brazil. 1340. Engaging Youth in a Web Based Transition Intervention: Usability and Feasibility <strong>of</strong> Rheumtogrow.org. Peter Scal, Ann Garwick and Keith Horvath, University <strong>of</strong> Minnesota. 1341. FEAR (False ELISA Associated Rheumatic) Syndrome in Children. Donald P. Goldsmith 1 , Carolann Martucci 3 and Svetlana Lvovich 2 , 1 St Christopher Hosp Children/Drexel University <strong>College</strong> <strong>of</strong> Medicine, Philadelphia, PA, 2 St Christopher’s Hosp Children/Drexel University <strong>College</strong> <strong>of</strong> Medicine, Philadelphia, PA, 3 St Christopher’S Hospital for Children, Philadelphia, PA. 1342. Physiotherapy Management <strong>of</strong> Children with Hypermobility: A Review <strong>of</strong> an Out-Patient Self Management Exercise Programme. Susan M. Maillard 1 , David Adkins 2 , Elaine Haggart 2 and Swati Bhagat 2 , 1 Great Ormond Street Hospital, London, Maidenhead, United Kingdom, 2 Great Ormond Street Hospital, London, London, United Kingdom. 1343. Stress in Adolescents with Idiopathic Musculoskeletal Pain. Juliana Molina 2 , Flavia H. Santos 1 , Maria Sylvia Vitalle 2 , Maria Odete E. Hilário 2 , Maria Teresa R. A. Terreri 2 , Simone G. L. Silva 2 and Claudio A. Len 2 , 1 Universidade Estadual de São Paulo, Assis, São Paulo, Brazil, 2 Universidade Federal de São Paulo, São Paulo, Brazil. 1344. To Explore the Use <strong>of</strong> the PedsQL Subjective Questionnaire To Assess Levels <strong>of</strong> Fatigue in Children with Juvenile Dermatomyositis. Susan M. Maillard 1 , Amy Todd 2 , Kiran Nistala 3 , Clarissa Pilkington 2 and Abdul Hassan 2 , 1 Great Ormond Street Hospital, London, Maidenhead, United Kingdom, 2 Great Ormond Street Hospital, London, 3 Institute <strong>of</strong> Child Health, London. 1345. Utilizing Social Media To Reach Young Arthritis Patients. Jane S. Brandenstein 1 , Emily Cope 3 , Allison J. Kerr 2 , Ashley M. Boynes 2 , Carol D. Popp 2 and Lori Knapp 2 , 1 Freedom, PA, 2 W Pa Arthritis Foundation, Pittsburgh, PA, 3 WPa Arthritis Foundation, Pittsburgh, PA. 232 2010 Program Book
ACR/ARHP Poster Session C Halls B1 & B2 WEDNESDAY, NOVEMBER 10, 2010 Biology and Pathology <strong>of</strong> Bone and Joint: Osteoarthritis-Cartilage Degradation and Skeletal Turnover 1466. A Novel Serum Biomarker <strong>of</strong> Cartilage Destruction, Measured in OA and RA Patients, Is Significantly Associated with Kellgren-Lawrence Score. Anne C. Bay-Jensen 1 , Erik B. Dam 3 , Inger Byrjalsen 2 , Tanja Schubert 4 , Phillip Vergnaud 4 , Per Qvist 1 and Morten A. Karsdal 1 , 1 Cartilage Biology and Biomarkers, Denmark, 2 CCBR-Synarc, Denmark, 3 Nordic Bioscience Imaging, Denmark, 4 Synarc-Lyon, France. 1467. A Small Molecule c-Fos/AP-1 Inhibitor T-5224 Inhibits Osteoclastogenesis and Bone Resorption. Hidetoshi Murao 3 , Yukihiko Aikawa 4 , Akira Hashiramoto 1 , Tetsuya Yamamoto 4 , Hisaaki Chaki 4 , Hirokazu Narita 4 , Shuichi Hirono 2 and Shunichi Shiozawa 1 , 1 Department <strong>of</strong> Biophysics, Kobe University <strong>of</strong> Graduate School <strong>of</strong> Health Sciences/The Center for Rheumatic Diseases, Kobe University Hospital, Kobe, Japan, 2 Department <strong>of</strong> Pharmaceutical Sciences, School <strong>of</strong> Pharmacy, Kitasato University, Tokyo, Japan, 3 Research Laboratories, Toyama Chemical Co., Ltd, Toyama, Japan, 4 Research Laboratories, Toyama Chemical Co., Ltd, Toyama, Japan. 1468. Activation <strong>of</strong> Wnt and Bone Morphogenetic Protein Signalling Pathways in the Articular Cartilage in Frzb-/- Mice. Liesbet Lodewyckx 1 , Jeroen Eyckmans 3 , Frank P. Luyten 2 and Rik Lories 1 , 1 KU Leuven, Leuven, Belgium, 2 KU Leuven, Leuven, Belgium, 3 KU Leuven. 1469. Adenosine A1 Receptors Regulates RANKL-Induced Osteoclast Formation Via Regulation <strong>of</strong> c-fos and NFATc1 Expression. Wenjie He 2 , Tuere Wilder 2 and Bruce N. Cronstein 1 , 1 New York Univ Med Ctr, New York, NY, 2 NYU School <strong>of</strong> Medicine. 1470. Adenosine A2A Receptor Agonists: Can They Prevent/ Treat Joint Prosthesis Loosening? Aranzazu Mediero 1 , Sally R. Frenkel 2 , Tuere Wilder 1 , Igor Immerman 3 , Scott Hadley 3 , R. Damani Howell 3 , Maya Hawly 4 , Elie Sellam 4 and Bruce N. Cronstein 5 , 1 Department <strong>of</strong> Medicine, NYU Langone Medical Center, New York, NY, 2 Department <strong>of</strong> Orthopaedic Surgery, NYU Hospital for Joint Diseases, New York, NY, 3 Department <strong>of</strong> Orthopaedic Surgery, NYU Hospital for Joint Diseases, 4 Institut Supérieur des BioSciences de Paris, France, 5 New York Univ Med Ctr, New York, NY. 1471. Adenosine A2A Receptor Ligation Inhibits Osteoclast Formation. Aranzazu Mediero 1 , Firas M. Kara 1 , Maya Hawly 2 , Elie Sellam 2 and Bruce N. Cronstein 3 , 1 Department <strong>of</strong> Medicine, NYU School <strong>of</strong> Medicine, New York, NY, 2 Institut Supérieur des Biosciences de Paris, Creteil, Ile de France, France, 3 New York Univ Med Ctr, New York, NY. 1472. Alarmins S100A8 and S100A9 Skew Human Chondrocytes towards a Cartilage Breakdown Phenotype. Rik F. P. Schelbergen 4 , Peter L. van Lent 5 , Arjen B. Blom 5 , Annet Sloetjes 5 , Thomas Vogl 2 , Johannes Roth 1 and Wim B. Van Den Berg 3 , 1 Children’s Hospital Eastern Ontario, Ottawa, ON, Canada, 2 Institute <strong>of</strong> Immunology, Muenster, 3 Radboud Univ Nijmegen Med Cntr, Nijmegen, The Netherlands, 4 Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, 5 Radboud University Nijmegen Medical Centre. 1473. Analysis <strong>of</strong> Secretome from Mesenchymal Stem Cells from Human Umbilical Cord Strome during the Chondrogenesis. María C. Arufe 1 , Alexandre De la Fuente 2 , Jesús Mateos 4 , Patricia Fernández-Puente 4 , Esther Rendal 4 , Silvia Díaz 2 , Isaac Fuentes 2 , Francisco J. De Toro 2 and Francisco J. Blanco 3 , 1 INIBIC-Universidad de A Coruna, A Coruna, Osteoarticular and Aging Research Laboratory, Proteomics Unit-Associated Node to ProteoRed-Biomedical Research Center (INIBIC), Hospital Universitario A Coruna, La Coruna, Coruña, Spain, 2 INIBIC-Universidad de A Coruna, A Coruna, Spain, 3 INIBIC- Universidad de A Coruna, A Coruna, Spain. Osteoarticular and Aging Research Laboratory, Proteomics Unit-Associated Node to ProteoRed-Biomedical Research Center (INIBIC). Hospital Universitario A Coruna, La Coruna, Spain, 4 Osteoarticular and Aging Research Laboratory, Proteomics Unit-Associated Node to ProteoRed-Biomedical Research Center (INIBIC), Hospital Universitario A Coruña. La Coruña, Spain. 1474. Biochemical Markers <strong>of</strong> Bone Balance (CTX-I/Osteocalcin) Improve with Tocilizumab Treatment in a Population <strong>of</strong> RA Patients with an Inadequate Response to Anti-TNF Therapy. Morten Karsdal 2 , Thasia G. Woodworth 3 , Andy Kenwright 4 , Inger Byrjalsesn 1 , Adam Platt 4 and Georg Schett 5 , 1 CCBR Synarc, Ballerup, Denmark, 2 Nordic Bioscience, Herlev, Herlev, Denmark, 3 Roche Products Ltd., Welwyn, Welwyn Garden City, United Kingdom, 4 Roche, Welwyn, United Kingdom, 5 University <strong>of</strong> Erlangen-Nuremberg, Erlangen, Germany. 1475. Chondrogenic Differentiation <strong>of</strong> Bone Marrow Mesenchymal Stem Cells Grown on Type I Collagen and Heparan Sulfate Scaffolds. Silvia Díaz-Prado 4 , Emma Muiños 3 , C. G. Trejo- Iriarte 1 , D. Lozano 2 , N. García-Honduvilla 1 , Isaac Fuentes 3 , Francisco J. De Toro 3 , P. Esbrit 2 , Julia Buján 1 and Francisco J. Blanco 3 , 1 Department <strong>of</strong> Medical Specialties. University <strong>of</strong> Alcalá de Henares, Madrid, Spain, 2 Laboratory <strong>of</strong> Bone and Mineral Metabolism. Fundación Jiménez Díaz (Capio Group). Madrid, Spain, 3 Osteoarticular and Aging Res. Lab. CIBER-BBN, <strong>Rheumatology</strong> Div, INIBIC-Complejo Hosp, Univ. A Coruña, A Coruña, SPAIN, 4 Osteoarticular and Aging Res. Lab. CIBER-BBN. <strong>Rheumatology</strong> Div. INIBIC-Complejo Hosp. Univ. A Coruña, Coruña, Spain. 1476. CXCR1/2 Signalling Is Required but Is Not Sufficient To Maintain the Phenotypic Stability <strong>of</strong> Human Articular Chondrocytes. Joanna C. Sherwood 1 , Pramod Achan 2 , Giovanna Nalesso 2 , Costantino Pitzalis 2 and Francesco Dell’Accio 2 , 1 Barts and The London School <strong>of</strong> Medicine and Dentistry, Queen Mary University <strong>of</strong> London, London, United Kingdom, 2 Barts and The London School <strong>of</strong> Medicine and Dentistry, Queen Mary University <strong>of</strong> London. 1477. Effects <strong>of</strong> NSAIDs and the Cyclooxygenase-Inhibiting Nitric Oxide Donator (CINOD) NCX 429 on Human Chondrocytes and Cartilage from OA Patients. Manlio Bolla 1 , Serena Viappiani 2 , Mandar Dave 4 , Jyoti Patel 4 , Steven B. Abramson 3 and Mukundan Attur 3 , 1 NicOx Research, Sophia Antipolis, France, 2 NicOx Research, 3 NYU Hospital for Joint Diseases, New York, NY, 4 NYU Hospital for Joint Diseases. 1478. Endogeneous TIMP3 Induce Death Receptor Ligand- Independent Apoptosis in Mesenchymal Cells. Christina Wunrau 2 , Doreen Wendholt 3 , Noreen Pundt 3 , Thomas Pap 1 and Berno Dankbar 3 , 1 IEMM, University Hospital Muenster, Münster, Germany, 2 Institute <strong>of</strong> Experimental Musculoskeletal Medicine- IEMM, University Hospital Muenster, Münster, Germany, 3 Institute <strong>of</strong> Experimental Musculoskeletal Medicine-IEMM, University Hospital Muenster, Muenster, Germany. 2010 Program Book 233
- Page 1 and 2:
program B O O K Pre-Conference Cour
- Page 3 and 4:
program B O O K ABOUT ACR/ARHP EDUC
- Page 5 and 6:
TABLE OF CONTENTS ACCREDITATION . .
- Page 7 and 8:
TABLE OF CONTENTS ACR/ARHP Poster S
- Page 9 and 10:
TABLE OF CONTENTS Systemic Sclerosi
- Page 11 and 12:
the written consent of the ACR is p
- Page 13 and 14:
Shuttle Bus Service See shuttle sig
- Page 15 and 16:
ACR Resource Center Hours: Sunday,
- Page 17 and 18:
ACR Hotels + Map Complimentary shut
- Page 19 and 20:
to the premier meeting in rheumatol
- Page 21 and 22:
ACR Clinical Research Conference c/
- Page 23 and 24:
4:20 PM Germinal Center Reactions A
- Page 25 and 26:
3:30 PM Live Demonstration: Ultraso
- Page 27 and 28:
Upon completion of this session, pa
- Page 29 and 30:
MONDAY, NOVEMBER 8, 2010 ACR/ARHP R
- Page 31 and 32:
B301 Dermatological Manifestations
- Page 33 and 34:
Session Overview: The innate immune
- Page 35 and 36:
Upon completion of this session, pa
- Page 37 and 38:
B308 Inflammatory Eye Disease P/C M
- Page 39 and 40:
and insufficiency • recall source
- Page 41 and 42:
Session Overview: The advent of bio
- Page 43 and 44:
2:45 pm 641. Major Improvements in
- Page 45 and 46:
5 University of Twente and Medisch
- Page 47 and 48:
ACR/ARHP Combined Abstract Session
- Page 49 and 50:
REF 25th Anniversary Celebration 2:
- Page 51 and 52:
5:45 PM 699. Defining Latent and/or
- Page 53 and 54:
Lilian H. D. van Tuyl 8 , Karin Bri
- Page 55 and 56:
ACR REF Special Sessions 4:30 - 6:0
- Page 57 and 58:
REF 5K Run/Walk 6:00 - 8:00 am See
- Page 59 and 60:
• discuss the principles of early
- Page 61 and 62:
ACR Medical Aspects of Rheumatic Di
- Page 63 and 64:
10:00 am 1349. Work as a Daily Chal
- Page 65 and 66:
ACR Plenary Session II: Discovery 2
- Page 67 and 68:
B210 B301 Pediatrics: Periodic Feve
- Page 69 and 70:
Session Overview: As a clinical edu
- Page 71 and 72:
Thomas J. Murphy Ballroom Giant Cel
- Page 73 and 74:
3:45 PM 1367. Serum Urate Levels in
- Page 75 and 76:
A411 Rheumatoid Arthritis - Human E
- Page 77 and 78:
2:45 PM 1405. Development of a Visi
- Page 79 and 80:
4:30 PM Anti-citrullinated Protein
- Page 81 and 82:
of Experimental Orthopedics, Univer
- Page 83 and 84:
5:30 PM 1438. Mortality/Morbidity i
- Page 85 and 86:
5:30 PM 1456. Belimumab, a BLyS-Spe
- Page 87 and 88:
Develly 5 , Bernardo L. F. Fernande
- Page 89 and 90:
7:30 PM Role of IL-1 in Human Artic
- Page 91 and 92:
• compare the prevalence and epid
- Page 93 and 94:
6:45 PM Macrophage Activation Syndr
- Page 95 and 96:
Upon completion of this session, pa
- Page 97 and 98:
Session Overview: This roundtable d
- Page 99 and 100:
B303 Scleroderma: Systemic Sclerosi
- Page 101 and 102:
9:00 - 10:30 am - Poster Hall Morni
- Page 103 and 104:
• describe the role of IL-1 and I
- Page 105 and 106:
Session Overview: For the clinician
- Page 107 and 108:
• identify the aspects for day-to
- Page 109 and 110:
ACR Study Groups 1:00 - 2:00 PM B30
- Page 111 and 112:
Session Overview: Ultrasound and ma
- Page 113 and 114:
Session Overview: Fifty percent of
- Page 115 and 116:
1:20 PM Academic Rheumatology Seth
- Page 117 and 118:
ACR Concurrent Abstract Sessions 2:
- Page 119 and 120:
3:00 PM 2110. Rheumatologists on th
- Page 121 and 122:
2:45 PM 2133. Reasons for Decline i
- Page 123 and 124:
Session Overview: We are witnessing
- Page 125 and 126:
Session Overview: Systemic sclerosi
- Page 127 and 128:
Oaks, CA, 2 Amgen Inc., San Francis
- Page 129 and 130:
5:00 PM 2176. A Role of Autoimmune
- Page 131 and 132:
4:30 PM 2198. Association between V
- Page 133 and 134:
ARHP Concurrent Sessions 4:30 - 6:0
- Page 135 and 136:
THURSDAY, NOVEMBER 11, 2010 ACR/ARH
- Page 137 and 138:
• apply these basic statistics to
- Page 139 and 140:
9:15 AM The ACR/EULAR Definition of
- Page 141 and 142:
Immunology, Oslo University Hospita
- Page 143 and 144:
9:15 AM 2239. Factors Associated wi
- Page 145 and 146:
Upon completion of this session, pa
- Page 147 and 148:
Mikkel Østergaard 6 , Paul Emery 4
- Page 149 and 150:
Ende 4 , 1 Department of Rheumatolo
- Page 151 and 152:
ACR Poster Session A Cytokines, Med
- Page 153 and 154:
ACR Poster Session A 51. Associatio
- Page 155 and 156:
ACR Poster Session A 83. Respirator
- Page 157 and 158:
ACR Poster Session A 121. Bone Dens
- Page 159 and 160:
ACR Poster Session A 142. The Intra
- Page 161 and 162:
ACR Poster Session A 171. Early Pro
- Page 163 and 164:
ACR Poster Session A Pediatric Rheu
- Page 165 and 166:
ACR Poster Session A 233. Prevalenc
- Page 167 and 168:
ACR Poster Session A 266. Subtype S
- Page 169 and 170:
ACR Poster Session A 297. Body Weig
- Page 171 and 172:
ACR Poster Session A 325. Patient R
- Page 173 and 174:
ACR Poster Session A 356. Influence
- Page 175 and 176:
ACR Poster Session A 383. Efficacy
- Page 177 and 178:
ACR Poster Session A 409. Rituximab
- Page 179 and 180:
ACR Poster Session A 441. Recombina
- Page 181 and 182:
ACR Poster Session A 465. Immunoglo
- Page 183 and 184: ACR Poster Session A 496. IRF8 Alle
- Page 185 and 186: ACR Poster Session A 521. DC-STAMP
- Page 187 and 188: ACR Poster Session A 546. Prevalenc
- Page 189 and 190: ACR Poster Session A 571. Epidemiol
- Page 191 and 192: ACR Poster Session A 599. Validatio
- Page 193 and 194: ACR/ARHP Poster Session B Halls B1
- Page 195 and 196: ACR Poster Session B 767. Economic
- Page 197 and 198: ACR/ARHP Poster Session B 792. The
- Page 199 and 200: ACR/ARHP Poster Session B Universit
- Page 201 and 202: ACR/ARHP Poster Session B 848. Cell
- Page 203 and 204: ACR/ARHP Poster Session B 886. Scre
- Page 205 and 206: ACR/ARHP Poster Session B 909. Regu
- Page 207 and 208: ACR/ARHP Poster Session B 935. The
- Page 209 and 210: ACR/ARHP Poster Session B 967. Frac
- Page 211 and 212: ACR Poster Session B 993. Early Exp
- Page 213 and 214: ACR/ARHP Poster Session B 1022. Com
- Page 215 and 216: ACR/ARHP Poster Session B 1055. Son
- Page 217 and 218: ACR Poster Session B 1084. Gene Exp
- Page 219 and 220: ACR/ARHP Poster Session B 1111. Inc
- Page 221 and 222: ACR Poster Session B hiroshima Memo
- Page 223 and 224: ACR/ARHP Poster Session B 1166. Pre
- Page 225 and 226: ACR/ARHP Poster Session B 1199. Typ
- Page 227 and 228: ACR/ARHP Poster Session B 1225. Phy
- Page 229 and 230: ACR/ARHP Poster Session B 1262. Lat
- Page 231 and 232: ACR/ARHP Poster Session B 1294. End
- Page 233: ACR/ARHP Poster Session B 1321. Cha
- Page 237 and 238: ACR/ARHP Poster Session C 1495. S10
- Page 239 and 240: ACR/ARHP Poster Session C 1524. Inc
- Page 241 and 242: ACR/ARHP Poster Session C 1555. Pro
- Page 243 and 244: ACR/ARHP Poster Session C 1583. Ass
- Page 245 and 246: ACR/ARHP Poster Session C 1596. Gen
- Page 247 and 248: ACR/ARHP Poster Session C 1622. Flu
- Page 249 and 250: ACR/ARHP Poster Session C Miscellan
- Page 251 and 252: ACR/ARHP Poster Session C L. Woodwa
- Page 253 and 254: ACR/ARHP Poster Session C 1692. Res
- Page 255 and 256: ACR/ARHP Poster Session C 1719. Los
- Page 257 and 258: ACR/ARHP Poster Session C 1749. Con
- Page 259 and 260: ACR/ARHP Poster Session C 1780. Tow
- Page 261 and 262: ACR/ARHP Poster Session C 1804. Eff
- Page 263 and 264: ACR/ARHP Poster Session C Immunolog
- Page 265 and 266: ACR/ARHP Poster Session C 2 Departm
- Page 267 and 268: ACR/ARHP Poster Session C CA, 29 Un
- Page 269 and 270: ACR/ARHP Poster Session C 1900. IL-
- Page 271 and 272: ACR/ARHP Poster Session C 1930. Cor
- Page 273 and 274: ACR/ARHP Poster Session C 1958. The
- Page 275 and 276: ACR/ARHP Poster Session C 1988. Cha
- Page 277 and 278: ACR/ARHP Poster Session C 2015. CpG
- Page 279 and 280: ACR/ARHP Poster Session C 2038. Pri
- Page 281 and 282: ACR/ARHP Poster Session C 2070. Ass
- Page 283 and 284: REF Industry Roundtable-supported S
- Page 285 and 286:
REF Industry Roundtable-supported S
- Page 287 and 288:
INDUSTRY-SUPPORTED POST-CONFERENCE
- Page 289 and 290:
2010 ACR/ARHP Annual Meeting Leader
- Page 291 and 292:
2010 ACR/ARHP Annual Meeting Leader
- Page 293 and 294:
FLOOR PLANS 2010 Program Book 291
- Page 295 and 296:
VISIT THE EXHIBIT HALL New and inno
- Page 297 and 298:
EXHIBITORS La Lettre Du Rhumatologu
- Page 299 and 300:
ACKNOWLEDGEMENTS The ACR, the ARHP
- Page 301 and 302:
ACR/ARHP/REF STAFF LISTING Administ
- Page 303 and 304:
A Ahmed, Rafi, PhD T cell Memory .
- Page 305 and 306:
Cooper, Max D, MD Introduction . .
- Page 307 and 308:
Gerlag, Danielle Marie, MD, PhD The
- Page 309 and 310:
Physical Examination Skills for Imp
- Page 311 and 312:
Meroni, Pierluigi, MD Autoantibodie
- Page 313 and 314:
Rogers, Joan C, PhD, OTR/ L Underst
- Page 315 and 316:
Terkeltaub, Robert, MD Crystallizin
- Page 317 and 318:
A Aarden, L 1825 Aarrass, S 1519, 1
- Page 319 and 320:
Bakker, AAB 1095 Barendregt, B 753
- Page 321 and 322:
Boutin-Le Thi Huong, D 478 Bout-Tab
- Page 323 and 324:
Chatham, WW 457, 1146, 1454, 1457,
- Page 325 and 326:
Daudon, M 875 Daugas, E 2009 Davatc
- Page 327 and 328:
Ehst, B 758 Eicher, JL 688 Eisen, S
- Page 329 and 330:
Gabay, OH 1484 Gaber, T 630, 1418 G
- Page 331 and 332:
Guan, M 965 Guañabens, N 975 Gudbj
- Page 333 and 334:
Homme, CL 730 Honda, E 434 Hong, JY
- Page 335 and 336:
Kambayashi, T 1354 Kamdar, AA 1160
- Page 337 and 338:
Kuller, LH 71 Kumabe, M 1164 Kumaga
- Page 339 and 340:
Looney, C 941 Looney, MR 609 Looney
- Page 341 and 342:
McCarthy, GM 1109, 1306, 1426 McCau
- Page 343 and 344:
Myouzen, K 1577 Mysiw, WJ 2096 Mysl
- Page 345 and 346:
Pans, M 1834 Parra, ER 605, 887 Ped
- Page 347 and 348:
Radka, S 1174 Radner, H 296, 1745 R
- Page 349 and 350:
Sack, KE 1898 Sacli, SF 1312 Saddic
- Page 351 and 352:
1463, 2071, 2140, 2141 Singh, K 212
- Page 353 and 354:
Takahata, M 1492 Takasaki, Y 1731 T
- Page 355 and 356:
636 van Dongen, CJJ 90 Van Doornum,
- Page 357 and 358:
Witte, T 824, 1578, 1579, 2214 Witt
- Page 359 and 360:
A α-galactosylceramide 505 A2A kno
- Page 361 and 362:
Behcet’s syndrome 1284, 1288, 129
- Page 363 and 364:
cost-utility 759, 1539 couples 1324
- Page 365 and 366:
fibroblast like synoviocyte 27 fibr
- Page 367 and 368:
impact 1063, 1325 inactive disease
- Page 369 and 370:
methylation 826, 1253, 1489 methylt
- Page 371 and 372:
233, 234, 240, 243, 252, 262, 268,
- Page 373 and 374:
1599, 1600, 1603, 1605, 1606, 1609,
- Page 375 and 376:
1226, 1227, 1229, 1230, 1231, 1233,
- Page 377 and 378:
Abelson, Abby Goulder, MD Education
- Page 379 and 380:
Massarotti, Elena M, MD Systemic Lu
- Page 381 and 382:
ACR Annual Meeting fellowS-in-train
- Page 383 and 384:
NOTES 2010 Program Book 381
- Page 385 and 386:
Enbrel ® (etanercept) Brief Summar
- Page 387 and 388:
Prescription Enbrel ® (etanercept)